iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules

19 Nov 2022 , 01:35 AM

Alembic Pharmaceuticals has received final approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Cyclophosphamide Capsules 25 mg and 50 mg The approved ANDA is therapeutically equivalent to the reference listed drug product RLD Cyclophosphamide Capsules 25 mg and 50 mg of Hikma Pharmaceuticals USA Inc Cyclophosphamide Capsules is an alkylating drug indicated for the treatment of malignant disease and minimal change nephrotic syndrome in pediatric patients Cyclophosphamide Capsules 25 mg and 50 mg have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA

Related Tags

  • Announcements
  • BSE
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.